Following the retirement of previous Chairman, John Nicholson, at the end of 2019, the Gentronix Board of Directors welcomes Alan Morgan as non-executive Chairman. Alan joins the Gentronix Board with over 20 years of CRO experience gained at the likes of Covance, and ICON, following an earlier background in finance for both ICI Pharmaceuticals and Glaxo Wellcome. More recently, Alan was the co-founder and CEO of Concept Life Sciences, a private equity backed venture, and currently holds an executive role in a privately held biometrics CRO focused upon clinical data managementbiostatistical analysis and statistical programming services.

Alan brings to Gentronix a wealth of experience in scaling contract research activities, building strong management teams and enabling delivery of expanded service offerings whilst maintaining a keen focus on quality. His leadership and mentoring of the management team will support the business in its exciting period of growth and expansion, following inward investment from Northern VCTs managed by Mercia. Matt Tate, Managing Director at Gentronix, welcomed Alan to the Board

“Alan’s appointment as Chairman coincides with an exciting period of investment and growth at Gentronix. I look forward to working with Alan to continue the growth and expansion of Gentronix, and I’m sure Alan’s mentoring and leadership to the Board will be invaluable”.

On his appointment as Gentronix Chairman, Alan commented “I am delighted to join the company at a point where historical success has attracted further investment for growth.  The company has significant opportunities to expand its services because of the quality and agility that the team delivers.”

Gentronix Ltd is a leading provider of genetic toxicology and skin toxicology services to global customers, operating from GLP compliant laboratories at Alderley Park, Cheshire. The business plans to expand its service offering and capacity across the next 2 years to meet increased market demand, creating new skilled scientific jobs in the North West.